Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

February’s top stories: Cerulean’s dosing in therapy trial, Novartis Phase II study

Cerulean Pharma began dosing in a Phase II clinical trial of its lead candidate, CRLX101, in combination with Avastin (bevacizumab) for treatment of relapsed ovarian cancer, while Novartis reported that the Phase II study evaluating its investigational oral compound LDE225 (sonidegib) in advanced basal cell carcinoma (BCC) met its primary endpoint. Drugdevelopment-technology.com wraps-up the key headlines from February 2014.

Go Top